TECP
TYRA icon

Trails Edge Capital Partners’s Tyra Biosciences TYRA Stock Holding History

Trails Edge Capital Partners’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-700,000
Closed -$18.4M – 34
2025
Q4 		$18.4M Buy
+700,000
New +$12.9M 4.55% 9

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Trails Edge Capital Partners's TYRA Position: Q1 2026 in Review

Trails Edge Capital Partners sold out of Tyra Biosciences (TYRA) in Q1 2026, closing a stake of 700,000 shares — an estimated $18.4M sold.

Trails Edge Capital Partners first reported a position in TYRA in Q4 2025 and held it in 1 quarter. The position peaked at $18.4M in Q4 2025. 164 funds tracked by Wall St. Rank hold TYRA as of Q1 2026.

  • Trails Edge Capital Partners reported no remaining Tyra Biosciences position as of Q1 2026 after selling out during the quarter.
  • Trails Edge Capital Partners sold 700,000 Tyra Biosciences shares in Q1 2026, an estimated $18.4M.
  • Trails Edge Capital Partners first reported a position in Tyra Biosciences in Q4 2025 and held it in 1 quarter.
  • Trails Edge Capital Partners's Tyra Biosciences position peaked at $18.4M in Q4 2025.
  • 164 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2026.

Based on Trails Edge Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.